Generics are favoured by healthcare providers due to a variety pf reasons, according to author Roy G Beran .
Author Professor Roy G Beran, in a mini review, explains what generics are and what is meant by generic equivalence .
In a mini review, author Professor Roy G Beran explains how generics can be produced at a much lower cost than originator drugs .
Regulatory bioequivalence rules for generics are well established and recognized. However, proving bioequivalence may not always be so easy, especially with drugs with a narrow therapeutic index (NTI) .
Repurposing generic drugs for new indications could save time and money compared to developing new treatments and represent a cost-effective way of addressing unmet medical needs, argues a new article by a University of Michigan professor .
The modernization of the drug supply system for citizens as a multifaceted process that ensures the sustainable development of the national health system is the focus of attention of the economy, the state and society. In order to study this, authors from Russia carried out a study to analyse the availability of medicines for the population for the treatment of cardiovascular diseases in 2011 and 2019 .
A study comparing generic etoricoxib (ETO) to the originator drug Arcoxia  finds that the generic version of the drug is bioequivalent to the reference compound, according to the Association of Southeast Asian Nation (ASEAN) bioequivalence guidelines.
By 2023, pharmaceutical expenditure is expected to reach US$1.5 trillion . This causes significant strain on healthcare systems worldwide and work is underway to bring pharmaceuticals’ spending down.
Cancer is the leading cause of death worldwide. Currently, there are increasing concerns about the price of cancer medicines and how this can limit patient access to lifesaving treatments. Now, a new study published in Applied Health Economics and Health Policy  calls for strengthened pricing policies that can ensure affordable cancer treatment for all.
The passage in 1984 of the Hatch-Waxman Act set into motion sweeping changes to the US brand-name and generic drug competitive environment. It greatly increased generic drug competition for small-molecule drugs, by establishing a new abbreviated new drug application (ANDA) generic drug approval process that substantially reduced the time and cost associated with a generic drug marketing application submitted to the US Food and Drug Administration (FDA). In addition, it created incentives for challenges to brand-name drug patents, while also creating incentives for continued medical innovation and new drug development by drug innovators.